Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Yifan Jia,Xin Shu,Xiaoan Yang,Haixia Sun,Huijuan Cao,Hong Cao,Ka Zhang,Qihuan Xu,Gang Li,Yang Yang

DOI: https://doi.org/10.1186/s13287-020-01787-4

2020-07-10

Abstract:Abstract Background Umbilical cord mesenchymal stem cells (UCMSCs) have been demonstrated to have good therapeutic effects in the treatment of HBV-related liver diseases. However, the therapeutic effect of UCMSCs on HBV-related liver failure and liver cirrhosis and the variations in the efficacy of UCMSCs after different treatment courses remain poorly understood. Therefore, this study was designed to answer these two questions. Methods This was an observational study that retrospectively considered a 3-year period during which 513 patients who received stem cell infusion and met the criteria of hepatic failure and liver cirrhosis were identified from the databases of the Third Affiliated Hospital of Sun Yat-sen University. The eligible patients were categorized into the liver failure group and liver cirrhosis group. The two groups were divided into different subgroups according to the duration of stem cell therapy. In the liver failure group, group A received more than 4 weeks and group B received less than 4 weeks of stem cell therapy. In the liver cirrhosis group, patients who received more than 4 weeks of stem cell therapy belonged to group C, and the patients in group D received less than 4 weeks of stem cell therapy. The patients were followed up for 24 weeks. The demographics, clinical characteristics, biochemical factors, and model for end-stage liver disease (MELD) scores were recorded and compared among different groups. Results A total of 64 patients met the criteria for liver failure, and 59 patients met the criteria for liver cirrhosis. After UCMSC treatment, the levels of alanine aminotransferase (ALT), glutamic-oxaloacetic transaminase (AST), and total bilirubin (TBIL) at all postbaseline time points were significantly lower than those at baseline in the liver failure group and liver cirrhosis group; the prothrombin activity (PTA) and MELD scores gradually improved in only the liver failure group. Four weeks after UCMSC treatment, patients who received prolonged treatment with UCMSCs had a larger decrease in TBIL levels than patients who terminated treatment with UCMSCs. After more than 4 weeks of UCMSC treatment, there were no statistically significant differences in the changes in ALT, AST, TBIL, and PTA values and MELD scores between patients with liver failure who received prolonged treatment with UCMSCs and patients with liver cirrhosis who received prolonged treatment with UCMSCs at any time point. However, the median decrease and cumulative decrease in the TBIL level of patients with liver failure with a standard 4-week treatment course were larger than those of patients with liver cirrhosis with a standard 4-week treatment course. Conclusion Peripheral infusion of UCMSCs showed good therapeutic effects for HBV-related liver failure and liver cirrhosis. Prolonging the treatment course can increase the curative effect of UCMSCs for end-stage liver disease, especially for patients with cirrhosis.

cell biology,medicine, research & experimental,cell & tissue engineering

What problem does this paper attempt to address?

There are mainly two problems that this paper attempts to solve:

1. **What is the efficacy of umbilical cord mesenchymal stem cells (UCMSCs) in the treatment of HBV - related liver failure and cirrhosis?**
Although previous studies have shown that UCMSCs have a good therapeutic effect on HBV - related liver diseases, at present, less is known about their specific efficacy in HBV - related liver failure and cirrhosis and the influence of different treatment courses on their efficacy. Therefore, this study aims to evaluate the therapeutic effect of UCMSCs in these two diseases and explore the influence of different treatment courses on the efficacy.

2. **Are there differences in the efficacy of UCMSCs treatment with different treatment courses for patients with HBV - related liver failure and cirrhosis?**
The study analyzes the influence of different treatment courses on the treatment effect, especially the change of total bilirubin (TBIL) level, by comparing patients who receive UCMSCs treatment for more than 4 weeks and those who receive it for no more than 4 weeks. The study also compares the differences in the efficacy of liver failure and cirrhosis patients after receiving UCMSCs treatment with different treatment courses.

Through the research on these problems, the author hopes to provide new insights and basis for the clinical treatment of HBV - related liver failure and cirrhosis.